3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Trishula Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Trishula Therapeutics, Inc. | 194 | 2024-03-25 | 2026-05-13 |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6 - Solid Tumor, Adult | Phase 1 | Completed | Trishula Therapeutics, Inc. | 185 | 2020-03-30 | 2025-07-29 |
| TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers TTX-030, Pembrolizumab, Gemcitabine - Solid Tumor, Lymphoma | Phase 1 | Completed | Trishula Therapeutics, Inc. | 56 | 2019-04-10 | 2025-07-02 |
Neoplasms (3) · Pancreatic Neoplasms (3) · Neoplasm Metastasis (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1)
Gemcitabine (3) · 130-nm albumin-bound paclitaxel (2) · budigalimab (2) · pembrolizumab (2) · Docetaxel (1) · Taxes (1)
United States (3) · South Korea (2) · Australia (1) · France (1) · Italy (1) · Spain (1) · Taiwan (1)